Trump Announces 9 New Drug Pricing Deals With Pharma Companies

President Donald Trump announced on Monday that nine additional pharmaceutical companies have agreed to join his administration's initiative to lower U.S. drug prices, a move officials said would expand the program to cover approximately 90% of the domestic branded-drug market. The new agreements bring the total number of participating companies to 26, building on deals struck with 17 major drugmakers last year.

The companies signing the latest voluntary agreements are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. Under the terms, they will offer outpatient drugs to state Medicaid programs at "most-favored-nation" prices, which are benchmarked to the lowest rates paid in other developed countries. The administration has projected the broader pricing push could save federal and state Medicaid programs about $64.3 billion over a decade.

In addition to the pricing commitments, the nine companies pledged to invest at least $19.6 billion in U.S. drug manufacturing. Four of them-Astellas, Sun Pharma, Teva, and UCB-agreed to donate active pharmaceutical ingredients for key products to a federal strategic reserve aimed...